By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Simcyp Limited 

Blades Enterprise Centre
John Street
Sheffield    S2 4SU  United Kingdom
Phone: 44-0-114-292-2322 Fax: 44-0-114-292-2333

Simcyp Limited provides a platform for modelling and simulating in vivo drug absorption, distribution, metabolism and excretion (ADME) using routinely generated in vitro data. The Simcyp Simulator is the industry’s most sophisticated platform for the prediction of drug-drug interactions and pharmacokinetic outcomes in clinical populations. Simcyp’s clients form a Consortium which guides scientific R&D at the company. Simcyp also works closely with drug regulatory agencies and is supported by a scientific advisory board of world-renowned experts.

The Simcyp Simulator is updated annually in consultation the Consortium, which includes nine of the top ten pharmaceutical companies in the world. This ensures the platform meets the needs of the industry. Simcyp’s products and services enable Consortium members to take full advantage of pre-clinical data to identify and manage the limitations of candidate compounds and assess the impact of covariates prior to conducting studies in humans. This helps focus drug development resources and prioritise the right study, at the right time. As a result, unnecessary drug exposure to human volunteers and animals can be minimised.

Simcyp simulations can also help identify pivotal pre-clinical data requirements, which has proved valuable in redefining and optimising early drug development processes and procedures. Simcyp’s science team provides consultancy services on a range of ADME and pharmacokinetics/pharmacodynamics (PK-PD) issues. In addition, Simcyp regularly runs interactive workshops on the optimal use and interpretation of in vitro ADME data. Simcyp Limited is a rapidly expanding company and we are continually looking to recruit talented scientists in the areas of modelling and simulation, biostatistics, pharmacokinetics and clinical pharmacology.

Key Statistics

Ownership: Private

Web Site: Simcyp Limited

Company News
Certara Corporation’s Simcyp Limited Division Launches Quantitative Systems Toxicology Initiative 12/6/2016 9:54:42 AM
Simcyp Limited Releases Version 13 of Its Widely Used Simulato 8/28/2013 10:31:19 AM
Simcyp Limited Releases Version 12 of its Simulator, Extending its Lead in the Application of Population-Based Modelling and Simulation 8/1/2012 10:34:30 AM
Simcyp Limited Releases Version 12 of its Simulator, Extending its Lead in the Application of Population-Based Modelling and Simulation 8/1/2012 9:42:34 AM
Certara Corporation Announces Completion of Acquisition of Simcyp Limited 3/14/2012 6:32:03 AM
Simcyp Limited Acquired by Certara Corporation for $32 Million 2/24/2012 6:28:29 AM
Simcyp Limited Develops Virtual Laboratory Mouse for use in Cancer and Toxicology Research 1/18/2012 8:57:22 AM
Simcyp Limited Releases Virtual Chinese Patient Population as China Increases Its Dominance in the World Pharmaceutical Market 1/9/2012 9:26:08 AM
Simcyp Limited Adds Blood-Brain Barrier Models to Its Population-Based Simulator and Expands Its Pharmacodynamic Capabilities 8/5/2011 9:20:40 AM
Simcyp Limited Appoints Dr Iain Gardner as Head of Translational Science in DMPK 6/21/2011 10:40:19 AM